Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ONX-0914 (PR-957) TFA is a selective, noncompetitive, irreversible inhibitor targeting the chymotrypsin-like subunit (LMP7) of the immunoproteasome, effectively blocking cytokine production and mitigating the progression of experimental arthritis. With a K_i value of 5.2 μM against the mycobacterial proteasome, ONX-0914 TFA also facilitates the reactivation of latent HIV-1 by inducing p-TEFb activation through HSF-1 mediation [1] [2] [3].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | ONX-0914 (PR-957) TFA is a selective, noncompetitive, irreversible inhibitor targeting the chymotrypsin-like subunit (LMP7) of the immunoproteasome, effectively blocking cytokine production and mitigating the progression of experimental arthritis. With a K_i value of 5.2 μM against the mycobacterial proteasome, ONX-0914 TFA also facilitates the reactivation of latent HIV-1 by inducing p-TEFb activation through HSF-1 mediation [1] [2] [3]. |
Molecular Weight | 694.7 |
Formula | C33H41F3N4O9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ONX-0914 TFA inhibitor inhibit